Small molecules that directly target MYC and its interaction with cofactor MAX, resulting in its proteasomal degradation, have also been developed and tested in a MYC-driven prostate cancer murine model, exhibiting remarkable anti-tumor effects (73). The gene discussed is MYC; the disease is neoplasm.